Market Research Logo

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Small Cell Lung Cancer Therapeutics Market 2015-2019

About Small Cell Lung Cancer

Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.

TechNavio's analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.

Covered in this Report

TechNavio's report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Menarini
  • Sanofi
  • ZIOPHARM Oncology
Other Prominent Vendors
  • Alchemia
  • Amgen
  • Apotex
  • BioMarin Pharmaceutical
  • CellAct Pharma
  • Cerulean Pharma
  • Cipla
  • Cornerstone Pharmaceuticals
  • Curis
  • CytRx
  • Eli Lilly
  • Exelixis
  • Fresenius Kabi
  • Genentech
  • Hikma Pharmaceuticals
  • Hospira
  • Intas Pharmaceuticals
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Lundbeck
  • MabVax Therapeutics Holdings
  • Medac Pharma
  • MEI Pharma
  • Merck
  • MolMed
  • Mologen
  • Mylan
  • Nektar Therapeutics
  • Neotropix
  • Novartis
  • Novogen
  • OncoMed Pharmaceuticals
  • Ono Pharmaceutical
  • PharmaMar
  • Polaris Group
  • Sagent Pharmaceuticals
  • Shanghai Jinhe Bio-Technology
  • Spectrum Pharmaceuticals
  • STADA Arzneimittel
  • Stem CentRx
  • Sun Pharmaceuticals Industries
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Zydus Cadila Healthcare
  • Market Driver
  • High Unmet Need
  • For a full, detailed list, view our report
  • Market Challenge
  • High Cost of Treatment
  • For a full, detailed list, view our report
  • Market Trend
  • Strategic Alliances
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Small Cell Lung Cancer Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Small Cell Lung Cancer Therapeutics Market: Bristol-Myers Squibb Co., GlaxoSmithKline plc, Menarini Group, Sanofi SA and ZIOPHARM Oncology Inc.

Other Prominent Vendors in the market are: Alchemia, Amgen, Apotex, BioMarin Pharmaceutical, CellAct Pharma, Cerulean Pharma, Cipla, Cornerstone Pharmaceuticals, Curis, CytRx, Eli Lilly, Exelixis, Fresenius Kabi, Genentech, Hikma Pharmaceuticals, Hospira, Intas Pharmaceuticals, Karyopharm Therapeutics, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lundbeck, MabVax Therapeutics Holdings, Medac Pharma, MEI Pharma, Merck, MolMed, Mologen, Mylan, Nektar Therapeutics, Neotropix, Novartis, Novogen , OncoMed Pharmaceuticals, Ono Pharmaceutical, PharmaMar, Polaris Group, Sagent Pharmaceuticals, Shanghai Jinhe Bio-Technology, Spectrum Pharmaceuticals, STADA Arzneimittel, Stem CentRx, Sun Pharmaceuticals Industries, Takeda Pharmaceutical, Teva Pharmaceutical and Zydus Cadila Healthcare

Commenting on the report, an analyst from Technavio’s team said: “The strategic alliances among vendors are an important trend being witnessed in the market. These are expected to give these market players a competitive edge over the others. The companies can leverage their strengths, which is expected to prove mutually beneficial.”

According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Small cell lung cancer advances very fast, and the detection rate is low at the localized stage. Current treatment options cannot cure the disease; hence, the mortality rate is high. Therefore, drugs that cause disease remission in patients are expected to drive the growth of the market significantly.

Further, the report states that the high cost of treatments is a major factor that restricts the growth of the market. Drugs for treatment of the cancer are expensive and hence, get poor response from patients. Hospital costs add to the cost of treatment. The co-morbidities associated with small cell lung cancer also need to be treated, which increases the cost of treatment.

Companies Mentioned

Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Sanofi, ZIOPHARM Oncology, Alchemia, Amgen, Apotex , BioMarin Pharmaceutical, CellAct Pharma, Cerulean Pharma, Cipla , Cornerstone Pharmaceuticals, Curis, CytRx, Eli Lilly, Exelixis, FreseniusKabi, Genentech, Hikma Pharmaceuticals, Hospira, Intas Pharmaceuticals , Karyopharm Therapeutics, Kyowa Hakko Kirin , Ligand Pharmaceuticals, Lundbeck, MabVax Therapeutics Holdings, Medac Pharma, MEI Pharma, Merck , MolMed,Mologen, Mylan , Nektar Therapeutics, Neotropix, Novartis, Novogen , OncoMed Pharmaceuticals, Ono Pharmaceutical, PharmaMar, Polaris Group, Sagent Pharmaceuticals , Shanghai Jinhe Bio-Technology , Spectrum Pharmaceuticals,STADAArzneimittel, Stem CentRx, Sun Pharmaceuticals Industries , Takeda Pharmaceutical, Teva Pharmaceutical, Zydus Cadila Healthcare

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Disease Overview
    • Understanding the Disease
    • Classification
      • Table Classification of Lung Cancer
      • Small Cell Carcinoma
      • Combined Small Cell Carcinoma
    • Diagnosis
      • Table Techniques for Diagnosing Small Cell Lung Cancer
      • Physical Examination
      • Laboratory Tests
      • Chest X-ray
      • Sputum Cytology
      • CT Scan
      • Biopsy
      • Light and Electron Microscopy
      • Immunohistochemistry
    • Rate of Incidence and Prevalence
      • Table Incidence of Lung Cancer in WHO Regions
    • Staging
      • Table Staging of Small Cell Lung Cancer
      • Table Small Cell Lung Cancer by Stage
      • Table Five-year Survival Rate of Small Cell Lung Cancer Patients
    • Management
      • Table Stepwise Diagrammatic Representation of Management of Small Cell Lung Cancer (According to ESMO Guidelines)
    • Economic Burden
  • Introduction
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
    • Top Predictions
      • Table Top Predictions in Global Small Cell Lung Cancer Therapeutics Market
    • Five Forces Analysis
  • Pipeline Analysis
    • Table Pipeline Portfolio of Small Cell Lung Cancer Drugs
    • Key Information on the Pipeline Candidates
      • Palifosfamide (ZIO-201)
      • Ipilimumab+Etoposide+Cisplatin/Carboplatin
      • Ipilimumab
      • Enoxaparin Sodium
      • BAY1000394 (Roniciclib)
      • Nivolumab (ONO-4538/ BMS-936558)
      • BMS-986012
      • LY2940680
      • Sabarubicin (MEN 10755)
      • CAP7.1
      • SC16LD6.5
      • BIW-8962
      • AMG 479 (Ganitumab)
      • LY2510924
      • Trisenox
      • MGN1703
      • Tarextumab (OMP-59R5)
      • BMN 673 (Talazoparib Tosylate)
      • NGR-hTNF
      • CPI-613
      • Alisertib (MLN8237)
      • Vismodegib (GDC-0449, Erivedge)
      • Cabozantinib (XL184 or Cometriq)
      • Selinexor (KPT-330)
      • ADI-PEG 20 (Pegargiminase)
      • Etirinotecan Pegol (NKTR-102)
      • CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
      • NTX-010
      • Aldoxorubicin
      • HA-Irinotecan
      • Carfilzomib
      • Small Cell Lung Cancer Vaccine
      • GSK2879552
      • NV-344 (ME-344)
      • BMS-833923 (XL139)
      • PM01183 (Lurbinectedin)
      • LDE225 (Erismodegib or Sonidegib)
      • Belinostat
    • Timeline for Major Products under Development
      • Palifosfamide (ZIO-201)
        • Table Timeline of Palifosfamide (ZIO-201)
      • Sabarubicin (MEN 10755)
        • Table Timeline of Sabarubicin (MEN 10755)
  • Market Segmentation by Therapeutic Class of Drugs
    • Table Global Small Cell Lung Cancer Therapeutics Market by Therapeutic Class of Drugs
    • Alkylating Agents
    • Antimetabolites
    • Microtubule Inhibitors
    • Cytotoxic Antibiotics
    • Topoisomerase Inhibitors
    • Others
  • Market Segmentation by Route of Administration
    • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration
    • Oral
    • Parenteral
      • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration 2014
  • Market Segmentation by Dosage Form
    • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms
    • Solid
    • Liquid
      • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms 2014
  • Geographical Segmentation
    • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2014
    • Table Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2019
    • Small Cell Lung Cancer Market in Americas
      • Market Size and Forecast
        • Table Small Cell Lung Cancer Therapeutics Market in Americas 2014-2019 (US$ million)
    • Small Cell Lung Cancer Market in EMEA Region
      • Market Size and Forecast
        • Table Small Cell Lung Cancer Therapeutics Market in EMEA Region 2014-2019 (US$ million)
    • Small Cell Lung Cancer Market in APAC Region
      • Market Size and Forecast
        • Table Small Cell Lung Cancer Therapeutics Market in APAC Region 2014-2019 (US$ million)
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Bristol-Myers Squibb
      • GlaxoSmithKline
      • Menarini
      • Sanofi
      • ZIOPHARM Oncology
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Bristol-Myers Squibb
      • Key Facts
      • Business Overview
      • Key Product Offerings
        • Table Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
      • Revenue by Geography
        • Table Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • GlaxoSmithKline
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table GlaxoSmithKline: Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Sales by Geography
        • Table GlaxoSmithKline: Sales by Geography 2013
      • Pipeline Products
        • Table GlaxoSmithKline: Pipeline Products 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Menarini
      • Key Facts
      • Business Overview
      • Key Pipeline Products
        • Table Menarini: Key Pipeline Products
      • Recent Developments
      • SWOT Analysis
    • Sanofi
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • ZIOPHARM Oncology
      • Key Facts
      • Business Overview
      • Recent Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report